Results 21 to 30 of about 13,707 (310)
Frontiers in Pharmacology, 2023 Background: Mepolizumab has been approved by the FDA for add-on maintenance treatment of severe asthma with an eosinophilic phenotype. Real-world studies on mepolizumab-associated adverse events are limited. The present study aimed to explore mepolizumab-
Huqun Li +3 more
doaj +1 more source
ERJ Open ResearchBackground There is limited evidence on biomarkers associated with response to the monoclonal antibodies currently approved for asthma treatment. We sought to identify circulatory metabolites associated with response to treatment with mepolizumab or ...
Tanawin Nopsopon +7 more
doaj +2 more sources
Frontiers in Immunology, 2023 Introduction Clinical remission as a multicomponent treatment goal in severe asthma is being explored in clinical practice. This post hoc analysis used data from the REDES study to assess the proportion of patients with severe eosinophilic asthma ...
I. Pavord +12 more
semanticscholar +1 more source
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients
Allergy. European Journal of Allergy and Clinical Immunology, 2023 Asthma remission has emerged as a potential treatment goal. This study evaluated the effectiveness of two biologics (mepolizumab/omalizumab) in achieving asthma remission.
D. Thomas +28 more
semanticscholar +1 more source
Hospital Pharmacy, 2016 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Cada, Dennis J +2 more
openaire +3 more sources
Respirology Case Reports, 2023 Mepolizumab, a humanized anti‐IL‐5 monoclonal antibody used for severe asthma, results in a reduced rate of asthma exacerbation, improved lung function, reduced oral corticosteroid use, and improved quality of life.
Takahiro Matsuyama +9 more
doaj +1 more source
Allergy, Asthma & Clinical Immunology, 2023 Background The mainstay of treatment for eosinophilic granulomatosis with polyangiitis (EGPA) is systemic corticosteroid therapy; some patients also receive intravenous immunoglobulins, other immunosuppressive agents, and biologics.
Nami Masumoto +7 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Oral corticosteroids (OCS) are commonly used for the acute management of severe asthma exacerbations or as maintenance therapy; however, chronic use is associated with significant toxicities, e.g., osteoporosis. In the REal worlD Effectiveness and Safety
Christian Domingo +10 more
doaj +1 more source
Real-Life Effectiveness of Mepolizumab in Refractory Chronic Rhinosinusitis with Nasal Polyps
Biomedicines, 2023 The aim of this study was to evaluate the efficacy of mepolizumab in patients affected by chronic rhinosinusitis with nasal polyps (CRSwNP) in real-life.
M. S. Domínguez-Sosa +6 more
semanticscholar +1 more source
Biomedicines, 2022 Severe asthma (SA) is categorized into multiple overlapping phenotypes and clinical characteristics driven by complex mechanistic inflammatory pathways. Mepolizumab is a human monoclonal antibody effectively targeting interleukin-5 in severe eosinophilic
Ruperto González-Pérez +3 more
doaj +1 more source